

Bleeding Time

[View the current Bleeding Time InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Bleeding_Time.html) - Regularly Updated.

Recent Publications on Bleeding Time:



- [Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.](#)
*Background and purpose: Biological aspirin resistance (AR) has been...*20th November, 2009
Department of Neurology, Hallym University College of Medicine, Seoul,- Eur J Neurol. 2009 Nov 17. ([DOI Direct Link](#))
- [Targeted inhibition of the serotonin 5HT\(2A\) receptor improves coronary patency in an in vivo model of recurrent thrombosis.](#)
*Background: Release of serotonin and activation of serotonin 5HT(2A)...*20th November, 2009
Center for Platelet Function Studies, University of Massachusetts Medical- J Thromb Haemost. 2009 Nov 17. ([DOI Direct Link](#))
- [Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.](#)
*OBJECTIVE To investigate the potential for the future clinical use of a...*17th November, 2009
Urology Research Center, Department of Urology, Health Science Campus, The- BJU Int. 2009 Nov 13. ([DOI Direct Link](#))
- [Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo.](#)
*Platelet activation at a site of vascular injury is essential for the...*17th November, 2009
Division of Internal and Cardiovascular Medicine, Department of Internal- J Exp Med. 2009 Oct 26;206(11):2365-79. Epub 2009 Oct 5. ([DOI Direct Link](#))
- [Role of a non-hormonal oral anti-fibrinolytic hemostatic agent \(tranexamic acid\) for management of patients with dysfunctional uterine bleeding.](#)
*OBJECTIVE: Perimenopausal dysfunctional bleeding is a common complaint seen...*29th October, 2009
Department of Obstetrics and Gynecology, Cankiri Government Hospital,- Clin Exp Obstet Gynecol. 2009;36(3):163-5.
- [Haemostatic role and histopathological effects of a new haemostatic agent in a rat bladder haemorrhage model: an experimental trial.](#)
*OBJECTIVE To investigate the haemostatic efficacy and histopathological...*24th October, 2009
Department of Urology, Selcuk University, Meram School of Medicine, Konya,- BJU Int. 2009 Oct 22. ([DOI Direct Link](#))
- [Dengue hemorrhage in a mouse model.](#)
*Here we summarized our findings in the mouse model of the events that lead...*24th October, 2009
National Taiwan University, College of Medicine, Graduate Institute of- Ann N Y Acad Sci. 2009 Sep;1171 Suppl 1:E42-7. ([DOI Direct Link](#))
- [Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.](#)

- Haemophilia B is a X-chromosome linked disease characterised by a...*7th October, 2009
 CSL Behring GmbH, Emil-von-Behring-Str. 76, 35041 Marburg, Germany.- *Thromb Haemost.* 2009 Oct;102(4):634-44. ([DOI Direct Link](#))
- [The microtubule modulator RanBP10 plays a critical role in regulation of platelet discoid shape and degranulation.](#)
*Terminally mature megakaryocytes undergo dramatic cellular reorganization...*6th October, 2009
 Labor fur Padiatrische Molekularbiologie der Klinik fur Allgemeine- Blood. 2009 Oct 2. ([DOI Direct Link](#))
 - [Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects.](#)
*This study evaluated the pharmacodynamics and pharmacokinetics of...*2nd October, 2009
 Eli Lilly and Company.- *J Clin Pharmacol.* 2009 Sep 30. ([DOI Direct Link](#))
 - [Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.](#)
*PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity...*1st October, 2009
 Ludwig Center, Dana-Farber Cancer Institute and Harvard Medical School,- *Clin Cancer Res.* 2009 Oct 1;15(19):6232-40. Epub 2009 Sep 29. ([DOI Direct Link](#))
 - [Congenital tufted angioma with persistent low-grade coagulopathy.](#)
*Summary A female infant, born with a tufted angioma, developed a...*26th September, 2009
 Department of Dermatology, Luton and Dunstable Hospital, Luton, UK.- *Clin Exp Dermatol.* 2009 Sep 22. ([DOI Direct Link](#))
 - [The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases.](#)
*BACKGROUND: Mean platelet volume (MPV) is arousing increasing interest as...*23rd September, 2009
 Department of Internal Medicine, Aging and Nephrological Diseases,- *Int J Clin Pract.* 2009 Oct;63(10):1509-15. ([DOI Direct Link](#))
 - [Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis \(SISET\).](#)
*SYNOPSIS OF RECOMMENDATIONS: The Italian Society for Thrombosis and...*11th September, 2009
 Department of Angiology and Blood Coagulation M. Golinelli,- *Thromb Res.* 2009 Nov;124(5):e6-e12. Epub 2009 Sep 8. ([DOI Direct Link](#))

BioNews Results for Bleeding Time

- [Medical News: Xanodyne Announces FDA Approval Of Lysteda\(TM\) \(Tranexamic Acid\) For Treatment Of Women With Heavy Menstrual Bleeding](#)
BioFind: Nov 17 2009 1:06PM Matching: bleeding time
- [Medical News: Xanodyne Announces FDA Approval Of Lysteda\(TM\) \(Tranexamic Acid\) For Treatment Of Women With Heavy Menstrual Bleeding](#)
BioFind: Nov 17 2009 1:04PM Matching: bleeding time
- [Simon MacCorkindale has terminal cancer](#)
Virgin Media: Nov 9 2009 4:08PM Matching: bleeding time
- [Simon MacCorkindale has terminal cancer](#)
Family GP: Nov 9 2009 3:46PM Matching: bleeding time
- [Radial Approach to PCI Associated With Less Bleeding Relative to the Femoral Approach: Presented at CCC](#)
Doctors Guide: Oct 28 2009 2:47AM Matching: bleeding time
- [ZymoGenetics Former Medical Boss Leads Rival Startup, ProFibrix, With Drug For Bleeding](#)
Xconomy: Oct 26 2009 11:34AM Matching: bleeding time
- [Continuous Infusion Heparin in the Treatment of Venous Thromboembolism](#)
Michigan Pharmacists Association: Oct 19 2009 1:26AM Matching: bleeding time

- [Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel](#)

Pharma Live: Aug 31 2009 2:55PM Matching: bleeding time



Bleeding Time Patents:

- 7470712- [Amino-benzazoles as P2Y.sub.1 receptor inhibitors](#)
- 7517054- [Ink-jet recording head and ink-jet recording device](#)
- 7521247- [Cartridge for monitoring the function of a device for testing blood platelet function, method for function monitoring, and use of a test fluid](#)
- 7528104- [Peptides that bind to the erythropoietin receptor](#)
- 7531178- [Immunoadhesin comprising a glycoprotein VI domain](#)
- 7531524- [Modulators of coagulation factors with enhanced stability](#)
- 7534457- [Hemostatic mistura of ipomoea balatas leaves, methods of preparation and use thereof](#)
- 7550433- [Erythropoietin receptor peptide formulations and uses](#)
- 7550499- [Urea antagonists of P2Y.sub.1 receptor useful in the treatment of thrombotic conditions](#)
- 7553936- [Anti-TREM-like transcript-1 \(TLT-1\) antibodies and compositions](#)
- 7560268- [Process for manufacturing biochip, probe solution, and biochip](#)
- 7514543- [Polynucleotides encoding immunoadhesins comprising a glycoprotein VI domain](#)
- 7514405- [Methods for treating transplant rejection](#)
- 7511070- [Compounds and therapies for the prevention of vascular and non-vascular pathologies](#)
- 7470723- [Diphenylethylene compounds and uses thereof](#)
- 7482472- [Substituted isoindoles and their use](#)
- 7491266- [Black ink and ink set for inkjet recording](#)
- 7494971- [Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin](#)
- 7498146- [Stable factor VIII/von willebrand factor complex](#)
- 7501404- [Substituted azetidinones](#)
- 7504113- [Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions](#)
- 7504497- [Orally bioavailable compounds and methods for inhibiting platelet aggregation](#)
- 7510732- [Analgesic and anti-inflammatory composition](#)
- 7511066- [Antithrombotic aromatic ethers](#)
- 7566701- [Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics](#)
- 7566711- [Reverse-turn mimetics and method relating thereto](#)
- 7597888- [Glycoprotein VI and uses thereof](#)
- 7598377- [Inhibition of phosphoinositide 3-kinase .beta.](#)
- 7601838- [2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido \(3,4-b\) indole-3-carboxylic acid esters/amides useful as antithrombotic agents](#)
- 7608416- [Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk](#)
- 7608640- [Glycine betaine and its use](#)
- 7611707- [Glycoprotein VI antibodies and methods thereof](#)
- 7612075- [Substituted oxoazaheterocyclyl compounds](#)
- 7612096- [Methods for treatment, modification and management of radiculopathy using](#)

[1-oxo-2-\(2,6-dioxopiperidin-3yl\)-4-aminoisoindoline](#)

- 7615219- [Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia](#)
- 7615568- [Antithrombotic ethers](#)
- 7595201- [Device for measuring an analyte](#)
- 7592445- [Non-nucleotide composition and method for inhibiting platelet aggregation](#)
- 7592339- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7575886- [Analysis of sulfated polysaccharides](#)
- 7576111- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7576135- [Diamine derivatives](#)
- 7576181- [Method of administering porcine B-domainless fVIII](#)
- 7579444- [Polymer-factor IX moiety conjugates](#)
- 7582602- [Hirulog-like peptide and gene therapy](#)
- 7585856- [Resolvins: Biotemplates for novel therapeutic interventions](#)
- 7585860- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7589073- [Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics](#)
- 7592331- [Macrocyclic factor VIIa inhibitors useful as anticoagulants](#)
- 7618949- [Drug-eluting stents coated with P2Y.sub.12 receptor antagonist compound](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

